Skip to main content
. Author manuscript; available in PMC: 2009 Oct 15.
Published in final edited form as: J Neurosci. 2009 Apr 15;29(15):4846–4857. doi: 10.1523/JNEUROSCI.0563-09.2009

Figure 2. Effects of systemic CB1 receptor antagonist SR141716A on the break-point for cocaine in LgA and ShA rats.

Figure 2

SR141716A (SR, Rimonabant) was injected (i.p.) 30 min before the test session. Sessions under a PR schedule ended when rats did not achieve cocaine (0.5 mg/kg/infusion) reinforcement within 1 h. Data are expressed as the mean ± SEM of the number of infusions per session on the left axis and the break-point (maximal ratio per infusion) on the right axis. Bars on the left side are data from cocaine extended access (LgA) rats and bars on the right side are data from limited access (ShA) rats. Responding for cocaine was different under a PR schedule in vehicle-injected rats between the access conditions: #p<0.01 compared to ShA. SR141716A (0.3 and 1.0 mg/kg) decreased the break-point for cocaine selectively in LgA rats compared with vehicle-injected animals; the highest dose of SR141716A (3.0 mg/kg) had a significant effect in both LgA and ShA rats compared to their respective controls: *p<0.05, ***p<0.001 compared to vehicle-injected rats in the same access condition. Different from ShA vehicle-injected rats: #p<0.01.